Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Ibrutinib on QT/QTc in Healthy Subjects
NCT02271438Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2014
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ibrutinib in chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenström's macroglobulinemia (WM) and 1 more (6 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Change from baseline in QTc interval at Day 4 and Number of Participants with Adverse events at Day 12. Started Oct 2014; status: completed.
02
Drugs
ibrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)mantle cell lymphoma (MCL)Waldenström's macroglobulinemia (WM)chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT02271438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02271438.